Combat pneumococcal infections: Adhesins as candidates for protein- based vaccine development

Current Drug Targets

Volumn 13, Issue 3, 2012, Pages 323-337

  Gámez, Gustavo ^a,b   Hammerschmidt, Sven ^a  

^a UNIVERSITY OF GREIFSWALD   (Germany)

^b UNIVERSIDAD DE ANTIOQUIA   (Colombia)

Author keywords

Adhesins; Pathogenesis; Pneumococci; Vaccines; Virulence factors

Indexed keywords

ADHESIN; AUTOLYSIN A VACCINE; CHOLINE BINDING PROTEIN D VACCINE; PHOSPHORYLCHOLINE ESTERASE VACCINE; PILUS ISLET 2A VACCINE; PILUS ISLET 2B VACCINE; PLASMIN FIBRONECTIN BINDING PROTEIN A VACCINE; PNEUMOCOCCAL ADHERENCE VIRULENCE FACTOR A VACCINE; PNEUMOCOCCAL ADHERENCE VIRULENCE FACTOR B VACCINE; PNEUMOCOCCAL COLLAGEN LIKE PROTEIN A VACCINE; PNEUMOCOCCAL IRON ACQUISITION A VACCINE; PNEUMOCOCCAL IRON UPTAKE A VACCINE; PNEUMOCOCCAL PROTECTIVE PROTEIN A VACCINE; PNEUMOCOCCAL SERINE RICH REPEAT PROTEIN VACCINE; PNEUMOCOCCAL SURFACE ANTIGEN A VACCINE; PNEUMOCOCCAL SURFACE PROTEIN A VACCINE; PNEUMOCOCCAL SURFACE PROTEIN C VACCINE; PNEUMOCOCCUS VACCINE; PROTEIN FOR CELL WALL SEPARATION GROUP B STREPTOCOCCI VACCINE; PUTATIVE PROTEINASE MATURATION PROTEIN A VACCINE; RLR REGULATED GENE A VACCINE; RLR REGULATED GENE B VACCINE; RLR REGULATED GENE C VACCINE; SERINE THREONINE PROTEIN KINASE VACCINE; SORTASE; STREPTOCOCCAL LIPROTEIN ROTAMASE A VACCINE; UNCLASSIFIED DRUG;

BACTERIAL COLONIZATION; BACTERIAL LOAD; BACTERIAL VIRULENCE; BACTERIUM ADHERENCE; DRUG BINDING; DRUG TARGETING; EXTRACELLULAR MATRIX; HUMAN; IMMUNE EVASION; IMMUNE RESPONSE; MORBIDITY; MORTALITY; NONHUMAN; PNEUMOCOCCAL INFECTION; PROTEIN INTERACTION; PROTEIN LOCALIZATION; REVIEW; STREPTOCOCCUS PNEUMONIA; STREPTOCOCCUS PNEUMONIAE; VACCINATION;

ADHESINS, BACTERIAL; ANIMALS; BACTERIAL PROTEINS; DRUG DISCOVERY; HUMANS; PNEUMOCOCCAL INFECTIONS; PNEUMOCOCCAL VACCINES;

EID: 84857133789     PISSN: 13894501     EISSN: 18735592     Source Type: Journal    
DOI: 10.2174/138945012799424697     Document Type: Review

References (169)

1. Austrian R. Some aspects of the pneumococcal carrier state. J Antimicrob Chemother 1986; 18(Suppl A): 5-45.
2. Bogaert D, van Belkum A, Sluijter M, et al. Colonisation by Streptococcus pneumoniae and Staphylococcus aureus in healthy children. Lancet 2004; 363(9424): 1871-1872.
3. Cartwright K. Pneumococcal disease in Western Europe: burden of disease, antibiotic resistance and management. Eur J Pediatr 2002; 161(4): 188-195.
4. Musher DM. How contagious are common respiratory tract infections? N Engl J Med 2003; 348(13): 1256-1266.
5. Henrichsen J. Six newly recognized types of Streptococcus pneumoniae. J Clin Microbiol 1995; 33(10): 2759-2762.
6. Park IH, Pritchard DG, Cartee R, Brandao A, Brandileone MC, Nahm MH. Discovery of a new capsular serotype (6C) within serogroup 6 of Streptococcus pneumoniae. J Clin Microbiol 2007; 45(4): 1225-12233.
7. Ghaffar F, Friedland IR, McCracken GH, Jr. Dynamics of nasopharyngeal colonization by Streptococcus pneumoniae. Pediatr Infect Dis J 1999; 18(7): 638-646.
8. Dawid S, Roche AM, Weiser JN. The blp bacteriocins of Streptococcus pneumoniae mediate intraspecies competition both in vitro and in vivo. Infect Immun 2007; 75(1): 443-451.
9. Lysenko ES, Ratner AJ, Nelson AL, Weiser JN. The role of innate immune responses in the outcome of interspecies competition for colonization of mucosal surfaces. PLoS Pathog 2005; 1(1): e1.
10. Gillespie SH. Aspects of pneumococcal infection including bacterial virulence, host response and vaccination. J Med Microbiol 1989; 28(4): 237-248.
11. Hare KM, Morris P, Smith-Vaughan H, Leach AJ. Random colony selection versus colony morphology for detection of multiple pneumococcal serotypes in nasopharyngeal swabs. Pediatr Infect Dis J 2008; 27(2): 178-180.
12. Brugger SD, Hathaway LJ, Muhlemann K. Detection of Streptococcus pneumoniae strain cocolonization in the nasopharynx. J Clin Microbiol 2009; 47(6): 1750-1756.
13. Lloyd-Evans N, O'Dempsey TJ, Baldeh I, et al. Nasopharyngeal carriage of pneumococci in Gambian children and in their families. Pediatr Infect Dis J 1996; 15(10): 866-871.
14. Atkinson W, Hamborsky J, McIntyre L, Wolfe S. Pneumococcal disease. Epidemiology and Prevention of Vaccine-Preventable Diseases Centers for Disease Control and Prevention. 11th ed. Washington DC: Public Health Foundation 2009. pp. 217-229.
15. Niederman MS, Mandell LA, Anzueto A, et al. Guidelines for the management of adults with community-acquired pneumonia. Diagnosis, assessment of severity, antimicrobial therapy, and prevention. Am J Respir Crit Care Med 2001; 163(7): 1730-1754.
16. Gilbert K, Fine MJ. Assessing prognosis and predicting patient outcomes in community-acquired pneumonia. Semin Respir Infect 1994; 9(3): 140-152.
17. Ware LB, Matthay MA. The acute respiratory distress syndrome. N Engl J Med 2000; 342(18): 1334-1349.
18. Rubenfeld GD, Caldwell E, Peabody E, et al. Incidence and outcomes of acute lung injury. N Engl J Med 2005; 353(16): 1685-1693.
19. Scott JA, Hall AJ, Muyodi C, et al. Aetiology, outcome, and risk factors for mortality among adults with acute pneumonia in Kenya. Lancet 2000; 355(9211): 1225-1230.
20. Rudan I, Tomaskovic L, Boschi-Pinto C, Campbell H. Global estimate of the incidence of clinical pneumonia among children under five years of age. Bull World Health Organ 2004; 82(12): 895-903.
21. Metlay JP, Fishman NO, Joffe M, Edelstein PH. Impact of pediatric vaccination with pneumococcal conjugate vaccine on the risk of bacteremic pneumococcal pneumonia in adults. Vaccine 2006; 24(4): 468-475.
22. Balakrishnan I, Crook P, Morris R, Gillespie SH. Early predictors of mortality in pneumococcal bacteraemia. J Infect 2000; 40(3): 256-261.
23. Lim WS, Macfarlane JT, Boswell TC, et al. Study of community acquired pneumonia aetiology (SCAPA) in adults admitted to hospital: implications for management guidelines. Thorax 2001; 56(4): 296-301.
24. Kadioglu A, Weiser JN, Paton JC, Andrew PW. The role of Streptococcus pneumoniae virulence factors in host respiratory colonization and disease. Nat Rev Microbiol 2008; 6(4): 288-301.
25. Kupronis BA, Richards CL, Whitney CG. Invasive pneumococcal disease in older adults residing in long-term care facilities and in the community. J Am Geriatr Soc 2003; 51(11): 1520-1525.
26. WHO. The global burden of disease: 2004 update. World Health Organization 2008.
27. Musher DM. Infections caused by Streptococcus pneumoniae: clinical spectrum, pathogenesis, immunity, and treatment. ClinInfect Dis 1992; 14(4): 801-807.
28. Mulholland K. Strategies for the control of pneumococcal diseases. Vaccine 1999; 17(Suppl 1): S79-S84.
29. Pletz MW, Maus U, Krug N, Welte T, Lode H. Pneumococcal vaccines: mechanism of action, impact on epidemiology and adaption of the species. Int J Antimicrob Agents 2008; 32(3): 199-206.
30. McGee L. The coming of age of niche vaccines? Effect of vaccines on resistance profiles in Streptococcus pneumoniae. Curr Opin Microbiol 2007; 10(5): 473-478.
31. Lynch JP, 3rd, Zhanel GG. Streptococcus pneumoniae: epidemiology and risk factors, evolution of antimicrobial resistance, and impact of vaccines. Curr Opin Pulm Med 2010; 16(3): 217-225.
32. Brueggemann AB, Pai R, Crook DW, Beall B. Vaccine escape recombinants emerge after pneumococcal vaccination in the United States. PLoS Pathog 2007; 3(11): e168.
33. Munoz-Almagro C, Jordan I, Gene A, Latorre C, Garcia-Garcia JJ, Pallares R. Emergence of invasive pneumococcal disease caused by nonvaccine serotypes in the era of 7-valent conjugate vaccine. Clin Infect Dis 2008; 46(2): 174-182.
34. Whitney CG. Impact of conjugate pneumococcal vaccines. Pediatr Infect Dis J 2005; 24(8): 729-730.
35. Whitney CG, Farley MM, Hadler J, et al. Decline in invasive pneumococcal disease after the introduction of proteinpolysaccharide conjugate vaccine. N Engl J Med 2003; 348(18): 1737-1746.
36. Singleton RJ, Hennessy TW, Bulkow LR, et al. Invasive pneumococcal disease caused by nonvaccine serotypes among alaska native children with high levels of 7-valent pneumococcal conjugate vaccine coverage. JAMA 2007; 297(16): 1784-1792.
37. Pilishvili T, Lexau C, Farley MM, et al. Sustained reductions in invasive pneumococcal disease in the era of conjugate vaccine. J Infect Dis 2010; 201(1): 32-41.
38. Janson H, Carln B, Cervin A, et al. Effects on the ciliated epithelium of protein D-producing and -nonproducing nontypeable Haemophilus influenzae in nasopharyngeal tissue cultures. J Infect Dis 1999; 180(3): 737-746.
39. Vesikari T, Wysocki J, Chevallier B, et al. Immunogenicity of the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) compared to the licensed 7vCRM vaccine. Pediatr Infect Dis J 2009; 28(4 Suppl): S66-S76.
40. CDC). CfDCaP. Invasive pneumococcal disease in young children before licensure of 13-valent pneumococcal conjugate vaccine - United States, 2007. MMWR Morb Mortal Wkly Rep 2010; 59(9): 253-257.
41. Kieninger DM, Kueper K, Steul K, et al. Safety, tolerability, and immunologic noninferiority of a 13-valent pneumococcal conjugate vaccine compared to a 7-valent pneumococcal conjugate vaccine given with routine pediatric vaccinations in Germany. Vaccine 2010; 28(25): 4192-4203.
42. Pai R, Moore MR, Pilishvili T, Gertz RE, Whitney CG, Beall B. Postvaccine genetic structure of Streptococcus pneumoniae serotype 19A from children in the United States. J Infect Dis 2005; 192(11): 1988-1995.
43. Kyaw MH, Lynfield R, Schaffner W, et al. Effect of introduction of the pneumococcal conjugate vaccine on drug-resistant Streptococcus pneumoniae. N Engl J Med 2006; 354(14): 1455-1463.
44. Goossens H, Ferech M, Coenen S, Stephens P. Comparison of outpatient systemic antibacterial use in 2004 in the United States and 27 European countries. Clin Infect Dis 2007; 44(8): 1091-1095.
45. Linares J, Ardanuy C, Pallares R, Fenoll A. Changes in antimicrobial resistance, serotypes and genotypes in Streptococcus pneumoniae over a 30-year period. Clin Microbiol Infect 2010; 16(5): 402-410.
46. Low DE. Changing trends in antimicrobial-resistant pneumococci: it's not all bad news. Clin Infect Dis 2005; 41 Suppl 4: S228-S233.
47. Jacobs MR, Koornhof HJ, Robins-Browne RM, et al. Emergence of multiply resistant pneumococci. N Engl J Med 1978; 299(14): 735-740.
48. Klugman KP. Pneumococcal resistance to antibiotics. Clin Microbiol Rev 1990; 3(2): 171-196.
49. Ardanuy C, Tubau F, Pallares R, et al. Epidemiology of invasive pneumococcal disease among adult patients in barcelona before and after pediatric 7-valent pneumococcal conjugate vaccine introduction, 1997-2007. Clin Infect Dis 2009; 48(1): 57-64.
50. Felmingham D, White AR, Jacobs MR, et al. The Alexander Project: the benefits from a decade of surveillance. J Antimicrob Chemother 2005; 56(Suppl 2): ii3-ii21.
51. Jenkins SG, Brown SD, Farrell DJ. Trends in antibacterial resistance among Streptococcus pneumoniae isolated in the USA: update from PROTEKT US Years 1-4. Ann Clin Microbiol Antimicrob 2008; 7: 1.
52. Felmingham D, Canton R, Jenkins SG. Regional trends in betalactam, macrolide, fluoroquinolone and telithromycin resistance among Streptococcus pneumoniae isolates 2001-2004. J Infect 2007; 55(2): 111-118.
53. Lipsitch M, Whitney CG, Zell E, Kaijalainen T, Dagan R, Malley R. Are anticapsular antibodies the primary mechanism of protection against invasive pneumococcal disease? PLoS Med 2005; 2(1): e15.
54. Rasko DA, Moreira CG, Li de R, et al. Targeting QseC signaling and virulence for antibiotic development. Science 2008; 321(5892): 1078-1080.
55. Rasko DA, Sperandio V. Anti-virulence strategies to combat bacteria-mediated disease. Nat Rev Drug Discov 2010; 9(2): 117-128.
56. Kadioglu A, Brewin H, Hartel T, et al. Pneumococcal protein PavA is important for nasopharyngeal carriage and development of sepsis. Mol Oral Microbiol 2010; 25(1): 50-60.
57. Pracht D, Elm C, Gerber J, et al. PavA of Streptococcus pneumoniae modulates adherence, invasion, and meningeal inflammation. Infect Immun 2005; 73(5): 2680-2689.
58. Holmes AR, McNab R, Millsap KW, et al. The pavA gene of Streptococcus pneumoniae encodes a fibronectin-binding protein that is essential for virulence. Mol Microbiol 2001; 41(6): 1395-1408.
59. Schwarz-Linek U, Hook M, Potts JR. The molecular basis of fibronectin-mediated bacterial adherence to host cells. Mol Microbiol 2004; 52(3): 631-641.
60. Polissi A, Pontiggia A, Feger G, et al. Large-scale identification of virulence genes from Streptococcus pneumoniae. Infect Immun 1998; 66(12): 5620-5629.
61. Orihuela CJ, Radin JN, Sublett JE, Gao G, Kaushal D, Tuomanen EI. Microarray analysis of pneumococcal gene expression during invasive disease. Infect Immun 2004; 72(10): 5582-5596.
62. Ogunniyi AD, Giammarinaro P, Paton JC. The genes encoding virulence-associated proteins and the capsule of Streptococcus pneumoniae are upregulated and differentially expressed in vivo. Microbiology 2002; 148(Pt 7): 2045-2053.
63. Marra A, Lawson S, Asundi JS, Brigham D, Hromockyj AE. In vivo characterization of the psa genes from Streptococcus pneumoniae in multiple models of infection. Microbiology 2002; 148(Pt 5): 1483-1491.
64. Hava DL, Camilli A. Large-scale identification of serotype 4 Streptococcus pneumoniae virulence factors. Mol Microbiol 2002; 45(5): 1389-1406.
65. Meinke A, Henics T, Nagy E. Bacterial genomes pave the way to novel vaccines. Curr Opin Microbiol 2004; 7(3): 314-320.
66. Rappuoli R. Reverse vaccinology, a genome-based approach to vaccine development. Vaccine 2001; 19(17-19): 2688-2691.
67. Rappuoli R. Conjugates and reverse vaccinology to eliminate bacterial meningitis. Vaccine 2001; 19(17-19): 2319-2322.
68. Wizemann TM, Heinrichs JH, Adamou JE, et al. Use of a whole genome approach to identify vaccine molecules affording protection against Streptococcus pneumoniae infection. Infect Immun 2001; 69(3): 1593-1598.
69. Barocchi MA, Ries J, Zogaj X, et al. A pneumococcal pilus influences virulence and host inflammatory responses. Proc Natl Acad Sci USA 2006; 103(8): 2857-2862.
70. Zysk G, Bongaerts RJ, ten Thoren E, Bethe G, Hakenbeck R, Heinz HP. Detection of 23 immunogenic pneumococcal proteins using convalescent-phase serum. Infect Immun 2000; 68(6): 3740-3743.
71. Giefing C, Meinke AL, Hanner M, et al. Discovery of a novel class of highly conserved vaccine antigens using genomic scale antigenic fingerprinting of pneumococcus with human antibodies. J Exp Med 2008; 205(1): 117-131.
72. Overweg K, Kerr A, Sluijter M, et al. The putative proteinase maturation protein A of Streptococcus pneumoniae is a conserved surface protein with potential to elicit protective immune responses. Infect Immun 2000; 68(7): 4180-4188.
73. Adrian PV, Bogaert D, Oprins M, et al. Development of antibodies against pneumococcal proteins alpha-enolase, immunoglobulin A1 protease, streptococcal lipoprotein rotamase A, and putative proteinase maturation protein A in relation to pneumococcal carriage and Otitis Media. Vaccine 2004; 22(21-22): 2737-2742.
74. Ling E, Feldman G, Portnoi M, et al. Glycolytic enzymes associated with the cell surface of Streptococcus pneumoniae are antigenic in humans and elicit protective immune responses in the mouse. Clin Exp Immunol 2004; 138(2): 290-298.
75. Bergmann S, Hammerschmidt S. Versatility of pneumococcal surface proteins. Microbiology 2006; 152(Pt 2): 295-303.
76. Hammerschmidt S. Adherence molecules of pathogenic pneumococci. Curr Opin Microbiol 2006; 9(1): 12-20.
77. Mitchell TJ. Virulence factors and the pathogenesis of disease caused by Streptococcus pneumoniae. Res Microbiol 2000; 151(6): 413-419.
78. Mitchell TJ, Alexander JE, Morgan PJ, Andrew PW. Molecular analysis of virulence factors of Streptococcus pneumoniae. Soc Appl Bacteriol Symp Ser 1997; 26: 62S-71S.
79. Nobbs AH, Lamont RJ, Jenkinson HF. Streptococcus adherence and colonization. Microbiol Mol Biol Rev 2009; 73(3): 407-450.
80. Bumbaca D, Littlejohn JE, Nayakanti H, Rigden DJ, Galperin MY, Jedrzejas MJ. Sequence analysis and characterization of a novel fibronectin-binding repeat domain from the surface of Streptococcus pneumoniae. Omics 2004; 8(4): 341-356.
81. Jedrzejas MJ. Unveiling molecular mechanisms of bacterial surface proteins: Streptococcus pneumoniae as a model organism for structural studies. Cell Mol Life Sci 2007; 64(21): 2799-2822.
82. Jensch I, Gamez G, Rothe M, et al. PavB is a surface-exposed adhesin of Streptococcus pneumoniae contributing to nasopharyngeal colonization and airways infections. Mol Microbiol 2010; 77(1): 22-43.
83. Yamaguchi M, Terao Y, Mori Y, Hamada S, Kawabata S. PfbA, a novel plasmin- and fibronectin-binding protein of Streptococcus pneumoniae, contributes to fibronectin-dependent adhesion and antiphagocytosis. J Biol Chem 2008; 283(52): 36272-36279.
84. Bruckner R, Nuhn M, Reichmann P, Weber B, Hakenbeck R. Mosaic genes and mosaic chromosomes-genomic variation in Streptococcus pneumoniae. Int J Med Microbiol 2004; 294(2-3): 157-168.
85. Paterson GK, Nieminen L, Jefferies JM, Mitchell TJ. PclA, a pneumococcal collagen-like protein with selected strain distribution, contributes to adherence and invasion of host cells. FEMS Microbiol Lett 2008; 285(2): 170-176.
86. Shivshankar P, Sanchez C, Rose LF, Orihuela CJ. The Streptococcus pneumoniae adhesin PsrP binds to Keratin 10 on lung cells. Mol Microbiol 2009; 73(4): 663-679.
87. Rose L, Shivshankar P, Hinojosa E, Rodriguez A, Sanchez CJ, Orihuela CJ. Antibodies against PsrP, a novel Streptococcus pneumoniae adhesin, block adhesion and protect mice against pneumococcal challenge. J Infect Dis 2008; 198(3): 375-383.
88. Sanchez CJ, Shivshankar P, Stol K, et al. The pneumococcal serine-rich repeat protein is an intra-species bacterial adhesin that promotes bacterial aggregation in vivo and in biofilms. PLoS Pathog 2010; 6(8).
89. Bagnoli F, Moschioni M, Donati C, et al. A second pilus type in Streptococcus pneumoniae is prevalent in emerging serotypes and mediates adhesion to host cells. J Bacteriol 2008; 190(15): 5480-5492.
90. Hilleringmann M, Giusti F, Baudner BC, et al. Pneumococcal pili are composed of protofilaments exposing adhesive clusters of Rrg A. PLoS Pathog 2008; 4(3): e1000026.
91. Hilleringmann M, Ringler P, Muller SA, et al. Molecular architecture of Streptococcus pneumoniae TIGR4 pili. EMBO J 2009; 28(24): 3921-3930.
92. Mandlik A, Swierczynski A, Das A, Ton-That H. Pili in Grampositive bacteria: assembly, involvement in colonization and biofilm development. Trends Microbiol 2008; 16(1): 33-40.
93. Telford JL, Barocchi MA, Margarit I, Rappuoli R, Grandi G. Pili in gram-positive pathogens. Nat Rev Microbiol 2006; 4(7): 509-519.
94. Falker S, Nelson AL, Morfeldt E, et al. Sortase-mediated assembly and surface topology of adhesive pneumococcal pili. Mol Microbiol 2008; 70(3): 595-607.
95. Izore T, Contreras-Martel C, El Mortaji L, et al. Structural basis of host cell recognition by the pilus adhesin from Streptococcus pneumoniae. Structure 2010; 18(1): 106-115.
96. Manzano C, Izore T, Job V, Di Guilmi AM, Dessen A. Sortase activity is controlled by a flexible lid in the pilus biogenesis mechanism of gram-positive pathogens. Biochemistry 2009; 48(44): 10549-10557.
97. Nelson AL, Ries J, Bagnoli F, et al. RrgA is a pilus-associated adhesin in Streptococcus pneumoniae. Mol Microbiol 2007; 66(2): 329-340.
98. Maisey HC, Quach D, Hensler ME, et al. A group B streptococcal pilus protein promotes phagocyte resistance and systemic virulence. FASEB J 2008; 22(6): 1715-1724.
99. Guiral S, Mitchell TJ, Martin B, Claverys JP. Competenceprogrammed predation of noncompetent cells in the human pathogen Streptococcus pneumoniae: genetic requirements. Proc Natl Acad Sci USA 2005; 102(24): 8710-8715.
100. Berry AM, Paton JC. Sequence heterogeneity of PsaA, a 37-kilodalton putative adhesin essential for virulence of Streptococcus pneumoniae. Infect Immun 1996; 64(12): 5255-5262.
101. Anderton JM, Rajam G, Romero-Steiner S, et al. E-cadherin is a receptor for the common protein pneumococcal surface adhesin A (PsaA) of Streptococcus pneumoniae. Microb Pathog 2007; 42(5-6): 225-236.
102. Brown JS, Gilliland SM, Holden DW. A Streptococcus pneumoniae pathogenicity island encoding an ABC transporter involved in iron uptake and virulence 1292. Mol Microbiol 2001; 40(3): 572-585.
103. Cron LE, Bootsma HJ, Noske N, Burghout P, Hammerschmidt S, Hermans PW. Surface-associated lipoprotein PpmA of Streptococcus pneumoniae is involved in colonization in a strainspecific manner. Microbiology 2009; 155(Pt 7): 2401-2410.
104. Hermans PW, Adrian PV, Albert C, et al. The streptococcal lipoprotein rotamase A (SlrA) is a functional peptidyl-prolyl isomerase involved in pneumococcal colonization. J Biol Chem 2006; 281(2): 968-976.
105. Marra A, Asundi J, Bartilson M, et al. Differential fluorescence induction analysis of Streptococcus pneumoniae identifies genes involved in pathogenesis. Infect Immun 2002; 70(3): 1422-1433.
106. Adamou JE, Heinrichs JH, Erwin AL, et al. Identification and characterization of a novel family of pneumococcal proteins that are protective against sepsis. Infect Immun 2001; 69(2): 949-958.
107. Hamel J, Charland N, Pineau I, et al. Prevention of pneumococcal disease in mice immunized with conserved surface-accessible proteins. Infect Immun 2004; 72(5): 2659-2670.
108. Rioux S, Neyt C, Di Paolo E, et al. Transcriptional regulation, occurrence and putative role of the Pht family of Streptococcus pneumoniae. Microbiology 2011; 157(Pt 2): 336-348.
109. Green BA, Zhang Y, Masi AW, et al. PppA, a surface-exposed protein of Streptococcus pneumoniae, elicits cross-reactive antibodies that reduce colonization in a murine intranasal immunization and challenge model. Infect Immun 2005; 73(2): 981-989.
110. Giefing C, Jelencsics KE, Gelbmann D, Senn BM, Nagy E. The pneumococcal eukaryotic-type serine/threonine protein kinase StkP co-localizes with the cell division apparatus and interacts with FtsZ in vitro. Microbiology 2010; 156(Pt 6): 1697-1707.
111. Barendt SM, Land AD, Sham LT, et al. Influences of capsule on cell shape and chain formation of wild-type and pcsB mutants of serotype 2 Streptococcus pneumoniae. J Bacteriol 2009; 191(9): 3024-3040.
112. Daley WP, Peters SB, Larsen M. Extracellular matrix dynamics in development and regenerative medicine. J Cell Sci 2008; 121(Pt 3): 255-264.
113. Jarvelainen H, Sainio A, Koulu M, Wight TN, Penttinen R. Extracellular matrix molecules: potential targets in pharmacotherapy. Pharmacol Rev 2009; 61(2): 198-223.
114. Barocchi MA, Censini S, Rappuoli R. Vaccines in the era of genomics: the pneumococcal challenge. Vaccine 2007; 25(16): 2963-2973.
115. Noske N, Kammerer U, Rohde M, Hammerschmidt S. Pneumococcal interaction with human dendritic cells: phagocytosis, survival, and induced adaptive immune response are manipulated by PavA. J Immunol 2009; 183(3): 1952-1963.
116. Rennemeier C, Hammerschmidt S, Niemann S, Inamura S, Zahringer U, Kehrel BE. Thrombospondin-1 promotes cellular adherence of gram-positive pathogens via recognition of peptidoglycan. FASEB J 2007; 21(12): 3118-3132.
117. Crawford SE, Stellmach V, Murphy-Ullrich JE, et al. Thrombospondin-1 is a major activator of TGF-beta1 in vivo. Cell 1998; 93(7): 1159-1170.
118. Bethe G, Nau R, Wellmer A, et al. The cell wall-associated serine protease PrtA: a highly conserved virulence factor of Streptococcus pneumoniae. FEMS Microbiol Lett 2001; 205(1): 99-104.
119. Kilian M, Poulsen K, Blomqvist T, et al. Evolution of Streptococcus pneumoniae and its close commensal relatives. PLoS One 2008; 3(7): e2683.
120. Blue CE, Paterson GK, Kerr AR, Berge M, Claverys JP, Mitchell TJ. ZmpB, a novel virulence factor of Streptococcus pneumoniae that induces tumor necrosis factor alpha production in the respiratory tract. Infect Immun 2003; 71(9): 4925-4935.
121. Bergmann S, Hammerschmidt S. Fibrinolysis and host response in bacterial infections. Thromb Haemost 2007; 98(3): 512-520.
122. Frolet C, Beniazza M, Roux L, et al. New adhesin functions of surface-exposed pneumococcal proteins. BMC Microbiol 2010; 10: 190.
123. Adkins JN, Varnum SM, Auberry KJ, et al. Toward a human blood serum proteome: analysis by multidimensional separation coupled with mass spectrometry. Mol Cell Proteomics 2002; 1(12): 947-955.
124. Bergmann S, Rohde M, Preissner KT, Hammerschmidt S. The nine residue plasminogen-binding motif of the pneumococcal enolase is the major cofactor of plasmin-mediated degradation of extracellular matrix, dissolution of fibrin and transmigration. Thromb Haemost 2005; 94(2): 304-311.
125. Bergmann S, Wild D, Diekmann O, et al. Identification of a novel plasmin(ogen)-binding motif in surface displayed alpha-enolase of Streptococcus pneumoniae. Mol Microbiol 2003; 49(2): 411-423.
126. Aplin AE, Howe AK, Juliano RL. Cell adhesion molecules, signal transduction and cell growth. Curr Opin Cell Biol 1999; 11(6): 737-744.
127. Hammerschmidt S, Tillig MP, Wolff S, Vaerman JP, Chhatwal GS. Species-specific binding of human secretory component to SpsA protein of Streptococcus pneumoniae via a hexapeptide motif. Mol Microbiol 2000; 36(3): 726-736.
128. Schubert WD, Urbanke C, Ziehm T, et al. Structure of internalin, a major invasion protein of Listeria monocytogenes, in complex with its human receptor E-cadherin. Cell 2002; 111(6): 825-836.
129. Blau K, Portnoi M, Shagan M, et al. Flamingo cadherin: a putative host receptor for Streptococcus pneumoniae. J Infect Dis 2007; 195(12): 1828-1837.
130. Gehlsen KR, Dillner L, Engvall E, Ruoslahti E. The human laminin receptor is a member of the integrin family of cell adhesion receptors. Science 1988; 241(4870): 1228-1229.
131. Agarwal V, Asmat TM, Luo S, Jensch I, Zipfel PF, Hammerschmidt S. Complement regulator factor H mediates a twostep uptake of Streptococcus pneumoniae by human cells. J Biol Chem 2010; 285(30): 23486-23495.
132. Bergmann S, Lang A, Rohde M, et al. Integrin-linked kinase is required for vitronectin-mediated internalization of Streptococcus pneumoniae by host cells. J Cell Sci 2009; 122(Pt 2): 256-267.
133. Agarwal V, Asmat TM, Dierdorf NI, Hauck CR, Hammerschmidt S. Polymeric immunoglobulin receptor-mediated invasion of Streptococcus pneumoniae into host cells requires a coordinate signaling of Src family of protein-tyrosine kinases, ERK and c-Jun N-terminal kinase. J Biol Chem 2010.
134. Agarwal V, Hammerschmidt S. Cdc42 and the Phosphatidylinositol 3-Kinase-Akt pathway are essential for PspC-mediated internalization of Pneumococci by respiratory epithelial cells. J Biol Chem 2009; 284(29): 19427-19436.
135. van der Poll T, Opal SM. Pathogenesis, treatment, and prevention of pneumococcal pneumonia. Lancet 2009; 374(9700): 1543-1556.
136. Paterson GK, Mitchell TJ. Innate immunity and the pneumococcus. Microbiology 2006; 152(2): 285-293.
137. Paterson GK, Orihuela CJ. Pneumococci: immunology of the innate host response. Respirology 2010.
138. Hammerschmidt S, Paterson GK, Bergmann S, Mitchell TJ. Pathogenesis of Streptococcus pneumoniae: adaptive immunity, innate immunity, cell biology virulence factors. In: Suttorp N, Welte T, Marre R, eds. Community-acquired pneumonia. Basel: Birkhäuser 2007. pp. 139-181.
139. Malley R, Henneke P, Morse SC, et al. Recognition of pneumolysin by Toll-like receptor 4 confers resistance to pneumococcal infection. Proc Natl Acad Sci USA 2003; 100(4): 1966-1971.
140. Cockeran R, Anderson R, Feldman C. The role of pneumolysin in the pathogenesis of Streptococcus pneumoniae infection. Curr Opin Infect Dis 2002; 15(3): 235-239.
141. Hollingshead SK, Becker R, Briles DE. Diversity of PspA: mosaic genes and evidence for past recombination in Streptococcus pneumoniae. Infect Immun 2000; 68(10): 5889-5900.
142. Iannelli F, Oggioni MR, Pozzi G. Allelic variation in the highly polymorphic locus pspC of Streptococcus pneumoniae 41. Gene 2002; 284(1-2): 63-71.
143. Melin M, Di Paolo E, Tikkanen L, et al. Interaction of pneumococcal histidine triad proteins with human complement. Infect Immun 2010; 78(5): 2089-2098.
144. Zipfel PF, Hallstrom T, Hammerschmidt S, Skerka C. The complement fitness factor H: role in human diseases and for immune escape of pathogens, like pneumococci. Vaccine 2008; 26 (Suppl 8): I67-174.
145. Hammerschmidt S, Agarwal V, Kunert A, Haelbich S, Skerka C, Zipfel PF. The host immune regulator factor H interacts via two contact sites with the PspC protein of Streptococcus pneumoniae and mediates adhesion to host epithelial cells. J Immunol 2007; 178(9): 5848-5858.
146. Jarva H, Janulczyk R, Hellwage J, Zipfel PF, Bjorck L, Meri S. Streptococcus pneumoniae evades complement attack and opsonophagocytosis by expressing the pspC locus-encoded Hic protein that binds to short consensus repeats 8-11 of factor H. J Immunol 2002; 168(4): 1886-1894.
147. Shaper M, Hollingshead SK, Benjamin WH, Jr, Briles DE. PspA protects Streptococcus pneumoniae from killing by apolactoferrin, and antibody to PspA enhances killing of pneumococci by apolactoferrin [corrected]. Infect Immun 2004; 72(9): 5031-5040.
148. Ren B, McCrory MA, Pass C, et al. The Virulence Function of Streptococcus pneumoniae Surface Protein A Involves Inhibition of Complement Activation and Impairment of Complement Receptor- Mediated Protection 1. J Immunol 2004; 173(12): 7506-7512.
149. Ren B, Szalai AJ, Hollingshead SK, Briles DE. Effects of PspA and antibodies to PspA on activation and deposition of complement on the pneumococcal surface 14. Infect Immun 2004; 72(1): 114-122.
150. Ren B, Szalai AJ, Thomas O, Hollingshead SK, Briles DE. Both family 1 and family 2 PspA proteins can inhibit complement deposition and confer virulence to a capsular serotype 3 strain of Streptococcus pneumoniae. Infect Immun 2003; 71(1): 75-85.
151. Tu AH, Fulgham RL, McCrory MA, Briles DE, Szalai AJ. Pneumococcal surface protein A inhibits complement activation by Streptococcus pneumoniae. Infect Immun 1999; 67(9): 4720-4704.
152. Johnston JW, Briles DE, Myers LE, Hollingshead SK. Mn2+- dependent regulation of multiple genes in Streptococcus pneumoniae through PsaR and the resultant impact on virulence. Infect Immun 2006; 74(2): 1171-1180.
153. Johnston JW, Myers LE, Ochs MM, Benjamin WH, Jr, Briles DE, Hollingshead SK. Lipoprotein PsaA in virulence of Streptococcus pneumoniae: surface accessibility and role in protection from superoxide. Infect Immun 2004; 72(10): 5858-5867.
154. McAllister LJ, Tseng HJ, Ogunniyi AD, Jennings MP, McEwan AG, Paton JC. Molecular analysis of the psa permease complex of Streptococcus pneumoniae. Mol Microbiol 2004; 53(3): 889-901.
155. Tseng HJ, McEwan AG, Paton JC, Jennings MP. Virulence of Streptococcus pneumoniae: PsaA mutants are hypersensitive to oxidative stress. Infect Immun 2002; 70(3): 1635-1639.
156. Hammerschmidt S, Bethe G, Remane PH, Chhatwal GS. Identification of pneumococcal surface protein A as a lactoferrinbinding protein of Streptococcus pneumoniae. Infect Immun 1999; 67(4): 1683-1687.
157. Dave S, Carmicle S, Hammerschmidt S, Pangburn MK, McDaniel LS. Dual roles of PspC, a surface protein of Streptococcus pneumoniae, in binding human secretory IgA and factor H. J Immunol 2004; 173(1): 471-477.
158. Smith BL, Hostetter MK. C3 as substrate for adhesion of Streptococcus pneumoniae. J Infect Dis 2000; 182(2): 497-508.
159. Janulczyk R, Iannelli F, Sjoholm AG, Pozzi G, Bjorck L. Hic, a novel surface protein of Streptococcus pneumoniae that interferes with complement function 46. J Biol Chem 2000; 275(47): 37257-37263.
160. Lu L, Ma Y, Zhang JR. Streptococcus pneumoniae recruits complement factor H through the amino terminus of CbpA. J Biol Chem 2006; 281(22): 15464-15474.
161. Elm C, Braathen R, Bergmann S, et al. Ectodomains 3 and 4 of human polymeric Immunoglobulin receptor (hpIgR) mediate invasion of Streptococcus pneumoniae into the epithelium. J Biol Chem 2004; 279(8): 6296-6304.
162. Zhang JR, Mostov KE, Lamm ME, et al. The polymeric immunoglobulin receptor translocates pneumococci across human nasopharyngeal epithelial cells. Cell 2000; 102(6): 827-837.
163. Lu L, Lamm ME, Li H, Corthesy B, Zhang JR. The human polymeric immunoglobulin receptor binds to Streptococcus pneumoniae via domains 3 and 4. J Biol Chem 2003; 278(48): 48178-48187.
164. Luo R, Mann B, Lewis WS, et al. Solution structure of choline binding protein A, the major adhesin of Streptococcus pneumoniae. EMBO J 2005; 24(1): 34-43.
165. Gianfaldoni C, Censini S, Hilleringmann M, et al. Streptococcus pneumoniae pilus subunits protect mice against lethal challenge. Infect Immun 2007; 75(2): 1059-1062.
166. Iannelli F, Chiavolini D, Ricci S, Oggioni MR, Pozzi G. Pneumococcal surface protein C contributes to sepsis caused by Streptococcus pneumoniae in mice. Infect Immun 2004; 72(5): 3077-3080.
167. Glover DT, Hollingshead SK, Briles DE. Streptococcus pneumoniae surface protein PcpA elicits protection against lung infection and fatal sepsis. Infect Immun 2008; 76(6): 2767-2776.
168. Bongaerts RJ, Heinz HP, Hadding U, Zysk G. Antigenicity, expression, and molecular characterization of surface-located pullulanase of Streptococcus pneumoniae. Infect Immun 2000; 68(12): 7141-7143.
169. Ogunniyi AD, Grabowicz M, Briles DE, Cook J, Paton JC. Development of a vaccine against invasive pneumococcal disease based on combinations of virulence proteins of Streptococcus pneumoniae. Infect Immun 2007; 75(1): 350-357.